Drug
pembrolizumab and lenvatinib
pembrolizumab and lenvatinib is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
not_yet_recruiting125%
recruiting250%
unknown125%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
NCT07368985
recruitingphase_2
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT06230471
recruitingphase_2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
NCT05185739
unknownphase_2
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
NCT04699071
Clinical Trials (4)
Showing 4 of 4 trials
NCT07368985Phase 2
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
NCT06230471Phase 2
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT05185739Phase 2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
NCT04699071Phase 2
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4